



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

02 FEB 2006

Arthur R. Crawford
Nixon & Vanderhye, P.C.
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808

In re Application of	:	
GEACH	:	
U.S. Application No.: 10/537,047	:	DECISION ON PETITION
PCT No.: PCT/GB03/04735	:	
Int. Filing Date: 03 November 2003	:	UNDER 37 CFR 1.137(b)
Priority Date: 01 November 2002	:	
Attorney Docket No.: 613-96	:	
For: PREPARATION COMPRISING 1,3 AND/OR 1,6	:	
BETA GLUCANS FOR THE TREATMENT OF	:	
INFECTIONS AND INFLAMMATIONS IN	:	
ANIMALS	:	

The petition to revive under 37 CFR 1.137(b) filed 02 June 2005 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "The delay in prosecuting this case (i.e. filing the declaration and paying the filing fee) was unintentional" is being interpreted to mean that the entire delay in providing payment of the full U.S. Basic National Fee from the due date for paying the fee until the filing of a grantable petition pursuant to this paragraph was unintentional. If this is an incorrect reading of applicant's statement applicant should contact the PCT Legal Office immediately. Applicant's statement and the prompt filing of the petition satisfies the requirement of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicant has now provided payment of the full, U.S. Basic National fee and the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

It is noted that applicant's petition and transmittal letter indicate the filing of a declaration in the present papers, however, no such declaration was included.

This application is being forwarded to the United States Designated/Elected Office (US/DO/EO) for continued processing including the issuance of a Notification of Missing Requirements (Form PCT/DO/EO/905) indicating that an executed oath or declaration of the inventor and payment of the \$65.00 surcharge for providing an executed oath or declaration later than thirty months from the earliest claimed priority date is required.

A handwritten signature in black ink, appearing to read 'Derek A. Putonen', written in a cursive style.

Derek A. Putonen
Attorney Advisor
Office of PCT Legal Administration
Tel: (571) 272-3294
Fax: (571) 273-0459